Should I buy Solventum (SOLV) stock or is it too late?

Solventum · Health Care · price $91

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $81 (-11 %), call made on July 10, 2026, maturing on July 10, 2027 (49 d ago).

The 5 reliable analysts $100+10 %

The 4 other firms $85.50-6.0 %

How to read it: the 5 reliable firms are not filtered by optimism — 4 aim above the price, 1 below, hence their $100 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.

In short — Should you invest in Solventum? Is it too late, still worth it? Analysts are fairly positive (67% buy, median target $100, i.e. +10%), and the most reliable on SOLV targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

67% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.
Median price target $100, i.e. +10% from the current price ($91).
The most reliable firm on SOLV, Piper Sandler (100% hit rate, 2 scored calls), targets $105 (call made on August 6, 2026, maturing on August 6, 2027) (+15%) in its most recent call, and $98 (call made on November 7, 2025, maturing on November 7, 2026) (+8%) in the one coming due soonest.
Reasonable valuation (P/E ~11) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 9 ratings, 2 are neutral and 1 is a sell.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on SOLV

Median target $100 (+10%) · 9 ratings · Buy consensus

Strong Buy00%

Buy667%

Hold222%

Sell111%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Solventum now?

We won't decide for you. The facts: 67% of analysts rate it a buy, median target $100 (+10%), and Piper Sandler (most reliable on SOLV, 100%) targets $105. Weigh that against valuation (P/E ~11). This is not personalized advice.

Is it too late to invest in Solventum?

Not according to analysts: the median target ($100) is still +10% above the current price ($91) (most reliable on SOLV: Piper Sandler, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Solventum still worth investing in?

It depends on the gap between the price ($91) and its estimated value: analysts target $100 on median (+10%), with 67% buys (most reliable on SOLV: Piper Sandler, 100%). Cross-check with their real reliability on SOLV and the cautions above. Information, not advice.

What's the main risk in buying SOLV?

The consensus is not unanimous: of 9 ratings, 2 are neutral and 1 is a sell.

→ Go deeper: the full Solventum profile (consensus, analyst reliability, price target, performance).